癌症中的PI3K：异构体的不同作用、激活模式及治疗靶点
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
作者信息
Thorpe Lauren M, Yuzugullu Haluk, Zhao Jean J
机构信息
1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA. [3] Program in Virology, Harvard Medical School, Boston, Massachusetts 02115, USA.
1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
出版信息
Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.
Abstract
Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers. In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.
摘要
磷脂酰肌醇3-激酶（PI3Ks）是响应细胞外刺激的细胞内信号传导的关键协调者。PI3K信号级联的过度激活是人类癌症中最常见的事件之一。在本综述中，我们讨论了关于特定PI3K亚型在正常和致癌信号传导中的作用、PI3K上调的不同方式以及该通路在临床上的靶向治疗现状和未来潜力的最新研究进展。
相似文献
1
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.
2
The relation between PI3K/AKT signalling pathway and cancer.
Gene. 2019 May 25;698:120-128. doi: 10.1016/j.gene.2019.02.076. Epub 2019 Mar 5.
3
Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.
Biochem Soc Trans. 2014 Feb;42(1):120-4. doi: 10.1042/BST20130255.
4
Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer.
Curr Top Microbiol Immunol. 2010;347:55-77. doi: 10.1007/82_2010_63.
5
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14.
6
Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.
Cancer Lett. 2012 Dec 28;325(2):125-31. doi: 10.1016/j.canlet.2012.06.009. Epub 2012 Jun 28.
7
Advances in subunits of PI3K class I in cancer.
Pathology. 2014 Apr;46(3):169-76. doi: 10.1097/PAT.0000000000000066.
8
PI3K/Akt signalling pathway and cancer.
Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007.
9
Targeting PI3K signaling in cancer: Challenges and advances.
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):361-366. doi: 10.1016/j.bbcan.2019.03.003. Epub 2019 Apr 1.
10
PI3K inhibitors for cancer therapy: what has been achieved so far?
Curr Med Chem. 2009;16(8):916-30. doi: 10.2174/092986709787581905.
引用本文的文献
1
Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target.
Antioxidants (Basel). 2025 Aug 16;14(8):1002. doi: 10.3390/antiox14081002.
2
Regulatory roles of circular RNAs in Wnt and other oncogenic signaling pathways in breast cancer progression: a comprehensive review.
Eur J Med Res. 2025 Aug 14;30(1):750. doi: 10.1186/s40001-025-02967-9.
3
Green Synthesis of Gold Nanoparticles and Their Cytotoxic Effect in Breast Cancer: An Experimental and Theoretical Study.
ACS Appl Bio Mater. 2025 Aug 18;8(8):7490-7503. doi: 10.1021/acsabm.5c01172. Epub 2025 Jul 31.
4
PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment.
MedComm (2020). 2025 Jul 30;6(8):e70295. doi: 10.1002/mco2.70295. eCollection 2025 Aug.
5
The tumor microbiome in cancer progression: mechanisms and therapeutic potential.
Mol Cancer. 2025 Jul 15;24(1):195. doi: 10.1186/s12943-025-02403-w.
6
Research progress on the anti-cancer mechanisms of edible salty-flavored Chinese materia medica.
Front Pharmacol. 2025 Jun 20;16:1598978. doi: 10.3389/fphar.2025.1598978. eCollection 2025.
7
PI3Kβ moonlights as a protein kinase: driving fatty acid metabolism and histone acetylation in cancer.
Cancer Biol Med. 2025 Jun 27;22(6):539-42. doi: 10.20892/j.issn.2095-3941.2025.0216.
8
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.
Biomedicines. 2025 May 28;13(6):1319. doi: 10.3390/biomedicines13061319.
9
Adaptation to Arginine Deprivation Leads to a More Aggressive, Therapy-Resistant Phenotype in HNSCC Cells.
Biomolecules. 2025 Jun 19;15(6):900. doi: 10.3390/biom15060900.
10
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation.
Nat Cancer. 2025 Jun 23. doi: 10.1038/s43018-025-00994-3.
本文引用的文献
1
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4.
2
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
3
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27.
4
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6395-400. doi: 10.1073/pnas.1323004111. Epub 2014 Apr 15.
5
PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function.
Dev Cell. 2014 Mar 31;28(6):647-58. doi: 10.1016/j.devcel.2014.01.022.
6
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.
7
PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
Cancer Cell. 2014 Mar 17;25(3):269-71. doi: 10.1016/j.ccr.2014.02.012.
8
Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.
9
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.
10
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Cancer Med. 2014 Apr;3(2):337-48. doi: 10.1002/cam4.191. Epub 2014 Feb 5.
Zotero 插件